Attendee list released for the Orphan Drugs & Rare Diseases 2016
13 September 2016 | By SMi
SMi Reports (13.09. 2016, London, UK): Alexion, BioMarin, Chiesi, MHRA, NICE to meet in London in October to discuss updates in the orphan drug landscape...
List view / Grid view
News
Chemotherapy alternative: research shows Chinese medicine kills cancer cells
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Compound kushen injection (CKI) has been used for years in Chinese clinics as an adjunct to western chemotherapy. Researchers used next generation...
Promising preclinical findings for Probiodrug’s glutaminyl cyclase inhibitor
8 September 2016 | By Caroline Richards, Editor, European Pharmaceutical Review & Drug Target Review
In a mouse model of inflammation (thioglycollate-induced peritonitis), PQ912 had an effect on recruitment of macrophages and eosinophils, and levels of chemokines and lipid mediators, which the company believes makes QC inhibition attractive for further evaluation as potential anti-inflammatory drug and/or resolution promoting agent...
JDRF gives $2.5 million for T1D diabetes research agreement with Sernova
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
A new research funding agreement aims to address people with severe type 1 diabetes (T1D) who are hypoglycemia unaware, a condition in which a person with...
Pancreatic tumour tissue development stopped by vitamin A process
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Through a process involving vitamin A, researchers from Imperial College London observed that it was possible to switch off pancreatic stellate cells...
HSRx antiviral drug tests effective against Zika virus
7 September 2016 | By Niamh Louise Marriott, Digital Content Producer
HSRx expects to begin human trials early in 2017 and will seek accelerated drug approval from the U.S. Food & Drug Administration...
BioMed X to collaborate with Johnson & Johnson on oral biofilm research
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
This research group is seeking the potential to unravel novel methods to remove bacterial biofilms from oral surfaces. Oral biofilms consist of a large variety of microorganisms embedded in a complex and robust extracellular matrix...
Rignotec raises €15 million to advance RIG-I targeted immuno-oncology therapeutics
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The funding will advance the ongoing development of Rigontec’s RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as accelerate the progress of lead candidate RGT100 towards the clinic...
Infra-red light detects early signs of oesophageal cancer
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers sprayed a dye on oesophageal tissue samples taken from people with Barrett’s oesophagus – a condition that risk cancer development...
Gene defect biomarker for targeted prostate cancer therapy
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The loss of CHD1, one of the most mutated genes in prostate tumours, sensitises human prostate cancer cells to different drugs, a biomarker for...
‘Liquid biopsy’ blood test spots new breast cancer subtype
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The blood test detects mutations to a gene called oestrogen receptor 1, or ESR1, which indicate that receptors for the female hormone oestrogen in the cancer cells, which are usually driven by the hormone, have evolved to stay permanently switched on without it – meaning hormonal treatments that block oestrogen…
MRC Technology, AstraZeneca, Asthma UK and British Lung Foundation to collaborate on respiratory disease research
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
A collaboration to investigate the link between epigenetics and respiratory disease and to find new drug treatments involves...
Takeda to enrol 5000 patients in giant multiple myeloma trial
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Takeda’s global non-interventional, observational multiple myeloma study is now enrolling patients, aiming to have 5,000 patients over three years with a goal of following each patient for a minimum of five years in an effort to track patterns in disease presentation, patient characteristics, treatment and outcomes, thereby enhancing the understanding…
CRISPR technology inactivates cancer mutations
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
CRISPR/Cas9 is likely one of the most revolutionary tools in biotechnology, with tremendous implications for a broad range of biological and medical disciplines. As programmable scissors this technology allows cleavage of DNA at predefined sites in the genome of cells...
Stem cell breakthrough unlocks mystery of inherited heart condition
31 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Using advanced stem cell technology, scientists from the Icahn School of Medicine at Mount Sinai have created a model of a heart condition called hypertrophic cardiomyopathy (HCM), an excessive thickening of the heart that is associated with a number of rare and common illnesses, some of which have a strong…